Brokerages Set LifeMD, Inc. (NASDAQ:LFMD) Target Price at $12.00

LifeMD, Inc. (NASDAQ:LFMD) has received an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $12.00.

A number of brokerages have recently weighed in on LFMD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of LifeMD in a report on Friday, September 20th. KeyCorp cut their price target on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, B. Riley assumed coverage on shares of LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 price objective for the company.

Hedge Funds Weigh In On LifeMD

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFMD. Vanguard Group Inc. increased its position in LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after acquiring an additional 128,701 shares during the period. Los Angeles Capital Management LLC increased its position in LifeMD by 852.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after acquiring an additional 108,822 shares during the period. Bank of New York Mellon Corp increased its position in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after acquiring an additional 91,183 shares during the period. Acadian Asset Management LLC increased its position in LifeMD by 261.8% in the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after acquiring an additional 84,413 shares during the period. Finally, X Square Capital LLC acquired a new position in LifeMD in the 2nd quarter valued at approximately $509,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Performance

NASDAQ LFMD opened at $4.38 on Friday. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The company has a market capitalization of $188.64 million, a P/E ratio of -6.26 and a beta of 1.23. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88. The firm has a 50-day moving average price of $4.83 and a two-hundred day moving average price of $6.67.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period in the previous year, the business posted ($0.23) earnings per share. Analysts anticipate that LifeMD will post -0.49 earnings per share for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.